Adult stem cells, and tissues derived from them, are currently believed less likely to initiate rejection after transplantation. This is because a patient's own cells could be expanded in culture, coaxed into assuming a specific cell type (differentiation), and then reintroduced into the patient. The use of adult stem cells and tissues derived from the patient's own adult stem cells would mean that the cells are less likely to be rejected by the immune system. This represents a significant advantage, as immune rejection can be circumvented only by continuous administration of immunosuppressive drugs, and the drugs themselves may cause deleterious side effects.
BUT, Research has been ongoing now for years as scientists have tried to determine whether stem cells from adult tissues have the same capabilities and potential as embryonic stem cells. Studies are constantly revealing new information and it is hoped that therapeutic applications will be developed from both sources. The question, however, perhaps remains: which source holds the advantage?
Development Potential
Adult stem cells are generally less flexible and versatile than embryonic stem cells. Embryonic stem cells have a far greater differentiation potential than adult stem cells simply because embryonic stem cells can develop into almost every type of cell in the human body. Conversely, adult stem cells may only develop into a limited number of cell types, so their potential applications are not as great as embryonic stem cells. Newer studies do, however, suggest that adult stem cells may have greater plasticity than was originally thought, which means that they may be able to differentiate into a greater range of specialized cell types. At present, however, it would appear that embryonic stem cells still have the advantage in their ability to differentiate more readily than adult stem cells.
On Adult stem cell side, the treatment for almost all of them is a bone marrow transplant, and most of those diseases are diseases we have always known were possible to treat with a bone marrow transplant. The transplant is a fairly versatile treatment, that can be effective for just about any disease that originates and is contained in the immune system. So it can treat just about every type of leukemia, many lymphomas, myleomas. It can also treat several non cancerous blood diseases like sickle cell anemia. It can treat several auto immune diseases. It can be used in conjunction with other organ transplants to give the patients a chance to come off the anti rejection meds. And its a possible future cure for aids.
The diseases a bone marrow transplant can treat are counted in adult stem cell treatments, because in reality its the stem cells in the marrow that make the transplant work. The same type of stem cells can also be found in the circulating blood and cord blood.
Research facts still continue....
Other articles and science reports on Adult Stem Cells.
Check, E., Cardiologists take heart from stem-cell treatment success, Nature 428(6986):880, 29 April 2004: "Adult stem cells have long been viewed as less flexible than embryonic stem cells, which can divide to produce any cell type in the body. But recent studies of human cells suggest that adult stem cells can also turn into many cell types, including heart, brain and liver cells."
Terada, N. et al., Bone marrow cells adopt the phenotype of other cells by spontaneous cells fusion, Nature (416(6880):542–545, 4 April 2002.
Cohen, P., Stem cells could save sight, New Scientist 175:(2354):18, 3 August 2002.
Stem cells do their stuff for Parkinson’s patient, New Scientist 174(2338):5, 13 April 2002.
Randerson, J., Stem cells fix the damage, New Scientist 177(2377):14, 11 January 2003.
Pluchino, S. et al., Injection of adult neurospheres induces recovery in a chronic model of multiple sclerosis, Nature 422(6933):688–694, 17 April 2003.
Jochen Ringe et al., Stem cells for regenerative medicine: advances in the engineering of tissues and organs, Naturwissenschaften 89(8), August 2002.
About the Formulator of StemEnhance - Christian Drapeau
Mr. Drapeau, a foremost scientist in the study of Aphanizomenon flos-aquae, holds a Masters of Science degree in Neurology and Neurosurgery from the Montreal Neurological Institute, an affiliate of McGill University in Montreal, Quebec, Canada. He has been extensively involved in the study of nutrition, naturopathy, and various natural therapies.
Most significantly, Mr. Drapeau collaborated with many scientists affiliated with Harvard University, McGill University, the University of Illinois, Oregon State University, the University of New Mexico, and the University of Mississippi in the study of the effects of blue-green algae (Aphanizomenon flos-aquae) on human health. Mr. Drapeau continues his involvement in the clinical study of AFA.
Circulating stem cells can reach various organs and become cells of that organ, helping such organ regain and maintain optimal health. Recent studies have suggested that the number of circulating stem cells is a key factor; the higher the number of circulating stem cells the greater is the ability of the body at healing itself. What happens to stem cells if they do not reach a tissue? Stem cells released from the bone marrow that do not reach a tissue simply return to the bone marrow after some timeCheck, E., Cardiologists take heart from stem-cell treatment success, Nature 428(6986):880, 29 April 2004: "Adult stem cells have long been viewed as less flexible than embryonic stem cells, which can divide to produce any cell type in the body. But recent studies of human cells suggest that adult stem cells can also turn into many cell types, including heart, brain and liver cells."
Terada, N. et al., Bone marrow cells adopt the phenotype of other cells by spontaneous cells fusion, Nature (416(6880):542–545, 4 April 2002.
Cohen, P., Stem cells could save sight, New Scientist 175:(2354):18, 3 August 2002.
Stem cells do their stuff for Parkinson’s patient, New Scientist 174(2338):5, 13 April 2002.
Randerson, J., Stem cells fix the damage, New Scientist 177(2377):14, 11 January 2003.
Pluchino, S. et al., Injection of adult neurospheres induces recovery in a chronic model of multiple sclerosis, Nature 422(6933):688–694, 17 April 2003.
Jochen Ringe et al., Stem cells for regenerative medicine: advances in the engineering of tissues and organs, Naturwissenschaften 89(8), August 2002.
About the Formulator of StemEnhance - Christian Drapeau
Mr. Drapeau, a foremost scientist in the study of Aphanizomenon flos-aquae, holds a Masters of Science degree in Neurology and Neurosurgery from the Montreal Neurological Institute, an affiliate of McGill University in Montreal, Quebec, Canada. He has been extensively involved in the study of nutrition, naturopathy, and various natural therapies.
Most significantly, Mr. Drapeau collaborated with many scientists affiliated with Harvard University, McGill University, the University of Illinois, Oregon State University, the University of New Mexico, and the University of Mississippi in the study of the effects of blue-green algae (Aphanizomenon flos-aquae) on human health. Mr. Drapeau continues his involvement in the clinical study of AFA.
United States Patent Patent No.: 6,814,961 B1 Date of Patent: November 9, 2004 Subj: METHOD FOR ENHANCING STEM CELL PHYSIOLOGY Inventors: Gitte S. Jensen and Christian Drapeau
